^
Association details:
| Biomarker: | NRAS Q61K |
|---|---|
| Cancer: | Melanoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
Excerpt:
To further confirm that NRASQ61K or NRASA146T mutations promote resistance to GSK2118436, we transfected plasmids encoding these mutations and the neomycin resistance gene into A375 cells....The mutant NRAS expressing clones were insensitive to cell growth inhibition by GSK2118436 (Fig. 2C) and GSK1120212...
DOI:
10.1158/1535-7163.MCT-11-0989
